WGO Graded Evidence: Strategies for Reducing the Prevalence of Antimicrobial Resistance

Level: Clinical Trials: 5 Abstracts

Legend:   : Special Mention  : Important  : Very Important  : Key Development
	Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. I Rapti, E Dimou, P Mitsoula, SJ Hadziyannis, Hepatology. 2007 Feb:307-13
	Race, insulin resistance and hepatic steatosis in chronic hepatitis C. HS Conjeevaram, DE Kleiner, JE Everhart, JH Hoofnagle, S Zacks, NH Afdhal, AS Wahed, Virahep-C Study Group, Hepatology. 2007 Jan:80-7
	Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. S Miehlke, K Hansky, W Schneider-Brachert, C Kirsch, A Morgner, A Madisch, E Kuhlisch, E Bæstlein, E Jacobs, E Bayerd&oeig;rffer, N Lehn, M Stolte, Aliment Pharmacol Ther. 2006 Jul 15:395-403
Supplementary evidence:
	Antimicrobial resistance associated with the treatment of bacterial vaginosis. RH Beigi, MN Austin, LA Meyn, MA Krohn, SL Hillier, Am J Obstet Gynecol. 2004 Oct:1124-9
	First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens. TT Koivisto, HI Rautelin, ME Voutilainen, MT Heikkinen, JP Koskenpato, MA Færkkilæ, Aliment Pharmacol Ther. 2005 Mar 15:773-82